Efficacy of combination treatment with Omalizumab and specific immunotherapy (Depigoid®) in adult and adolescent patients with seasonal allergic asthma and comorbid seasonal aller…

Background: Previous study data generated in patients with grass- and birch-pollen allergic seasonal rhinoconjunctivitis has demonstrated a statistically significant and clinically relevant superiority of the combination of Xolair® (Omalizumab) plus SIT versus SIT monotherapy. There is no data available of anti-IgE treatment in seasonal allergic asthma nor on its efficacy on SIT long-term treatment (improved immunmodulation). Objective: The purpose of this study was to demonstrate that preseasonal treatment and co-seasonal addition of Omalizumab to Depigoid® provide optimal benefit as for both efficacy and safet…